BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20100903)

  • 1. Beneficial electrophysiological effects of trimetazidine in patients with postischemic chronic heart failure.
    Cera M; Salerno A; Fragasso G; Montanaro C; Gardini C; Marinosci G; Arioli F; Spoladore R; Facchini A; Godino C; Margonato A
    J Cardiovasc Pharmacol Ther; 2010 Mar; 15(1):24-30. PubMed ID: 20100903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trimetazidine shortens QTc interval in patients with ischemic heart failure.
    Zemljic G; Bunc M; Vrtovec B
    J Cardiovasc Pharmacol Ther; 2010 Mar; 15(1):31-6. PubMed ID: 19966175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation.
    Belardinelli R; Lacalaprice F; Faccenda E; Volpe L
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):533-40. PubMed ID: 18797405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect.
    Belardinelli R; Solenghi M; Volpe L; Purcaro A
    Eur Heart J; 2007 May; 28(9):1102-8. PubMed ID: 17456483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Potentialities of cytoprotection in the treatment of chronic heart failure in patients with coronary heart disease].
    Fedorova TA; Il'ina IuV; Sotnikova TI; Rybakova MK
    Klin Med (Mosk); 2004; 82(11):15-20. PubMed ID: 15656392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy.
    Di Napoli P; Di Giovanni P; Gaeta MA; D'Apolito G; Barsotti A
    Am Heart J; 2007 Sep; 154(3):602.e1-5. PubMed ID: 17719313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
    Fragasso G; Piatti Md PM; Monti L; Palloshi A; Setola E; Puccetti P; Calori G; Lopaschuk GD; Margonato A
    Am Heart J; 2003 Nov; 146(5):E18. PubMed ID: 14597947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced transmural dispersion of repolarization in patients with J wave syndromes.
    Karim Talib A; Sato N; Sakamoto N; Tanabe Y; Takeuchi T; Saijo Y; Kawamura Y; Hasebe N
    J Cardiovasc Electrophysiol; 2012 Oct; 23(10):1109-14. PubMed ID: 22612896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [QT interval dispersion in hypertensive diabetics and in patients with hypertension with chronic heart failure without diabetes].
    Radman A; Murín J; Bulas J; Reptová A; Ravingerová T; Mikes P; Kozliková K; Ghanem W; Jaber J; Baqi L
    Vnitr Lek; 2003 Oct; 49(10):802-7. PubMed ID: 14682153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure.
    Fragasso G; Salerno A; Lattuada G; Cuko A; Calori G; Scollo A; Ragogna F; Arioli F; Bassanelli G; Spoladore R; Luzi L; Margonato A; Perseghin G
    Heart; 2011 Sep; 97(18):1495-500. PubMed ID: 21700755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial.
    Di Napoli P; Di Giovanni P; Gaeta MA; Taccardi AA; Barsotti A
    J Cardiovasc Pharmacol; 2007 Nov; 50(5):585-9. PubMed ID: 18030070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repercussions of cardiac resynchronization therapy on the ventricular repolarization of heart failure patients as assessed by body surface potential mapping.
    Pastore CA; Douglas RA; Samesima N; Martinelli Filho M; Nishioka SD; Kaiser E; Ramires JA
    Anadolu Kardiyol Derg; 2007 Jul; 7 Suppl 1():79-81. PubMed ID: 17584688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy.
    Marazzi G; Gebara O; Vitale C; Caminiti G; Wajngarten M; Volterrani M; Ramires JA; Rosano G; Fini M
    Adv Ther; 2009 Apr; 26(4):455-61. PubMed ID: 19396409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy.
    Belardinelli R; Cianci G; Gigli M; Mazzanti M; Lacalaprice F
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):611-5. PubMed ID: 18574390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QT dispersion and early arrhythmic risk during acute myocardial infarction.
    Ciolli A; Di Lorenzo M; Bevilacqua U; Lo Sardo G; Tripi M; Fidati R; Palamara A
    G Ital Cardiol; 1999 Dec; 29(12):1438-44. PubMed ID: 10687106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dispersion of the corrected QT and JT interval in the electrocardiogram of alcoholic patients.
    Corović N; Duraković Z; Misigoj-Duraković M
    Alcohol Clin Exp Res; 2006 Jan; 30(1):150-4. PubMed ID: 16433743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical and hemodynamic efficacy of selective beta-blocker bisoprolol and cytoprotector trimetazidine in the treatment of chronic cardiac failure in patients with ischemic heart disease].
    Fedorova TA; Il'ina IuV; Sotnikova TI; Rybakova MK; Loshchits NV
    Ter Arkh; 2004; 76(3):62-8. PubMed ID: 15108463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis.
    Zhang L; Lu Y; Jiang H; Zhang L; Sun A; Zou Y; Ge J
    J Am Coll Cardiol; 2012 Mar; 59(10):913-22. PubMed ID: 22381427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy.
    Flevari P; Parissis JT; Leftheriotis D; Panou F; Kourea K; Kremastinos DT
    Am J Cardiol; 2006 Dec; 98(12):1641-5. PubMed ID: 17145226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.
    Fragasso G; Palloshi A; Puccetti P; Silipigni C; Rossodivita A; Pala M; Calori G; Alfieri O; Margonato A
    J Am Coll Cardiol; 2006 Sep; 48(5):992-8. PubMed ID: 16949492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.